Kathryn Kopec
6 min
Ketamine serves as a critical pharmacological agent in the emergency department, functioning as a dissociative anesthetic with unique properties that distinguish it from traditional sedatives. Unlike many other agents, ketamine typically preserves spontaneous respirations and airway reflexes, making it a valuable option for procedural sedation, analgesia, and rapid sequence intubation (RSI).
The drug acts primarily as an NMDA receptor antagonist, but it also interacts with opioid receptors, dopamine, norepinephrine, and serotonin systems. This complex profile allows for a wide range of clinical applications. For analgesia, sub-dissociative doses are used to manage pain with minimal hemodynamic compromise. For agitation and procedural sedation, higher doses are required to achieve the necessary level of dissociation. The protocol emphasizes that clinicians must be prepared for the transient increases in blood pressure and heart rate that often accompany its administration.
Ketamine can be administered via intravenous (IV), intramuscular (IM), or intranasal (IN) routes, with specific dosing caps and concentration requirements to ensure patient safety. Because the sedative effects of ketamine can wear off within 15 to 30 minutes, the guidelines stress the importance of proactive planning for patient management, including potential re-dosing or the transition to longer-acting sedative infusions. While generally safe, clinicians must monitor for rare but significant adverse effects such as laryngospasm, hypersalivation, and emergence reactions. Management strategies for these side effects, such as the use of atropine for hypersalivation or midazolam for emergence reactions, are clearly defined to support safe clinical practice.
Alex: That explains why it's listed as second-line for post-intubation sedation. What's the reasoning there?
Sam: Titratability. In the ICU, the goal is often a stable, sustained depth of sedation over hours or days, and ketamine's sympathomimetic properties complicate hemodynamic monitoring in that setting. Agents like propofol or fentanyl are far easier to dial in over long time horizons. Ketamine gets reserved for situations where those agents are contraindicated or failing — hemodynamically fragile patients who can't tolerate the vasodilation propofol produces, for instance. [[RP_SECTION:route-and-pharmacokinetics|Route and Pharmacokinetics]]
Alex: The protocol covers multiple routes — IV, intramuscular, intranasal. Does the route meaningfully change the therapeutic window, or is it primarily about access?
Sam: Both, and they interact. An intramuscular dose has a slower onset but a longer duration than an IV push — the absorption kinetics shift the entire time course. That gives the clinician a useful degree of control: if you don't have IV access, the IM or intranasal routes aren't just workarounds, they're genuinely different pharmacokinetic profiles that can be matched to the clinical environment. Less precise, but sometimes more appropriate. [[RP_SECTION:monitoring-and-safety-protocols|Monitoring and Safety Protocols]]
Alex: The monitoring requirements are fairly intensive for a drug that preserves airway reflexes. Why is end-tidal CO₂ monitoring emphasized so heavily?
Sam: Because "preserves airway reflexes" is a probabilistic statement, not a guarantee. The protocol is clear that reflex loss can still occur, particularly when ketamine is combined with other sedatives or antipsychotics — which is common in the ED. End-tidal CO₂ gives you continuous, real-time ventilation data, so you catch that rare but dangerous complication before it becomes a crisis rather than after.
Alex: The weight-based dosing seems straightforward, but it doesn't account for metabolic variability or polypharmacy. That feels like a meaningful gap.
Sam: It is. Individual responses vary considerably — prior substance exposure, baseline sympathetic tone, concurrent medications all shift the dose-response curve in ways a static weight-based table can't capture. The emergence phenomenon is particularly hard to predict. The protocol is a starting point, not a substitute for real-time clinical judgment. The clinician still needs to be watching the patient and ready to adjust. [[RP_SECTION:future-of-dynamic-titration|Future of Dynamic Titration]]
Alex: Is there a plausible path toward more dynamic titration?
Sam: The logical direction is closed-loop systems integrating EEG-based depth-of-anesthesia monitoring with real-time capnography, using both signals to drive automated infusion adjustments. That would let you maintain the hemodynamic stability ketamine provides while reducing the risk of over-sedation at the tails of the distribution. We're not there clinically yet — for now, the safety margin still depends on the clinician's vigilance and their willingness to treat the protocol as a floor, not a ceiling.
Alex: That's a useful frame. Ketamine's pharmacology gives you a distinctive tool — one that trades the usual sedation-respiration tradeoff for a different set of constraints around hemodynamics and emergence. Understanding which patients sit in which part of that tradeoff is where the clinical judgment actually lives.
Sam: And that's precisely why the protocol is structured the way it is — not as a decision tree that removes judgment, but as a scaffold that makes the relevant tradeoffs legible under pressure. Thanks for listening to ResearchPod.